19 June 2013
Keywords: ionix, ix-1003, completes, phase, studies, trials, been
Article | 21 July 2003
Phase I trials have been successfully completed for Ionix Pharmaceuticals' IX-1003. The product is a proprietary intranasal
formulation of the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
© 2013 thepharmaletter.com